15th Dec 2020 09:29
(Alliance News) - AstraZeneca PLC on Tuesday said that its Imfinzi product has been recommended for marketing authorisation in the EU for less frequent, fixed-dose use in unresectable non-small cell lung cancer.
The additional dosing option is for 1,500 milligrams as a fixed dose every four weeks, and will be available to patients with locally advanced, unresectable NSCLC weighting more than 30 kilograms.
The positive opinion by the Committee for Medicinal Products for Human Use based its positive opinion on data from several Imfinzi clinical trials, including the Pacific phase three trial and Caspian phase three trial.
"The four-week dosing regimen will decrease the risk of exposure to infection in the healthcare setting, furthering our efforts to ensure continuity of care for cancer patients at high risk of complications during the pandemic. We look forward to offering non-small cell lung cancer patients in Europe an option that would reduce medical visits by extending dosing from two to four weeks," said Jose Baselga, executive vice president of Oncology R&D.
Shares in AstraZeneca were down 1.7% at 7,565.00 pence on Tuesday in London.
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca